We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+33.87%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$336M
AUM Growth
+$6.15M
Cap. Flow
-$5.31M
Cap. Flow %
-1.58%
Top 10 Hldgs %
38.74%
Holding
96
New
16
Increased
28
Reduced
16
Closed
29
Avg Time Held Equity + Options
3.4 quarters
Top 10 Avg Time Held Equity + Options
0.6 quarters
Top 20 Avg Time Held Equity + Options
0.8 quarters
Avg Time Held Equity only
3.5 quarters
Top 10 Avg Time Held Equity only
0.6 quarters
Top 20 Avg Time Held Equity only
1.7 quarters

Top Buys

Rank Stock Value
1
NUVL icon
Nuvalent
NUVL
+$11.9M
2
SNY icon
Sanofi
SNY
+$10.8M
3
MDT icon
Medtronic
MDT
+$10.3M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8.45M
5
CLDX icon
Celldex Therapeutics
CLDX
+$7.27M

Top Sells

Rank Stock Value
1
IMGN icon
Immunogen Inc
IMGN
+$20.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.2M
3
SLNO icon
Soleno Therapeutics
SLNO
+$8.43M
4
KRYS icon
Krystal Biotech
KRYS
+$8.3M
5
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.5%
2 Miscellaneous 3.5%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRUS icon
1
DELISTED
Merus
MRUS
$17.8M 5.28%
645,581
+145,581
+29% +$3.4M
2021 Q1
11 quarters
MRSN icon
2
DELISTED
Mersana Therapeutics
MRSN
$14.9M 4.43%
256,805
+56,805
+28% +$2.29M
2022 Q2
6 quarters
MORF icon
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$14.4M 4.3%
500,042
-90,787
-15% -$2.16M
2020 Q4
12 quarters
NUVL icon
4
DELISTED
Nuvalent
NUVL
$14.2M 4.23%
+193,000
New +$11.9M
2023 Q4
0 quarters
PSTX icon
5
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$12.5M 3.71%
3,705,779
+137,794
+4% +$355K
2021 Q4
8 quarters
MGNX icon
6
MacroGenics
MGNX
$218M
$12.1M 3.6%
1,258,641
-5,517
-0.4% -$38.1K
2022 Q3
5 quarters
RCKT icon
7
Rocket Pharmaceuticals
RCKT
$252M
$11.5M 3.41%
+382,672
New +$8.45M
2023 Q4
0 quarters
MDT icon
8
Medtronic
MDT
$119B
$11.1M 3.31%
+135,000
New +$10.3M
2023 Q4
0 quarters
SNY icon
9
Sanofi
SNY
$93.7B
$10.9M 3.26%
+220,000
New +$10.8M
2023 Q4
0 quarters
ORIC icon
10
Oric Pharmaceuticals
ORIC
$1.17B
$10.8M 3.2%
1,170,000
+46,655
+4% +$337K
2022 Q2
6 quarters
CLDX icon
11
Celldex Therapeutics
CLDX
$2.22B
$9.8M 2.92%
+247,215
New +$7.27M
2023 Q4
0 quarters
MRTX
12
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.81M 2.62%
150,000
– –
2023 Q2
2 quarters
OLMA icon
13
Olema Pharmaceuticals
OLMA
$614M
$8.05M 2.4%
573,830
+166,029
+41% +$2.23M
2023 Q2
2 quarters
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$5.96B
$8.01M 2.38%
174,248
-86,289
-33% -$2.72M
2023 Q2
2 quarters
URGN icon
15
UroGen Pharma
URGN
$1.87B
$7.88M 2.35%
525,404
+16,521
+3% +$214K
2023 Q3
1 quarter
XENE icon
16
Xenon Pharmaceuticals
XENE
$3.33B
$7.52M 2.24%
163,168
+109,172
+202% +$3.86M
2021 Q3
9 quarters
VCYT icon
17
Veracyte
VCYT
$3.47B
$6.81M 2.03%
247,723
+8,152
+3% +$197K
2021 Q1
11 quarters
PRAX icon
18
Praxis Precision Medicines
PRAX
$6.79B
$6.32M 1.88%
283,841
+9,313
+3% +$168K
2023 Q2
2 quarters
AKRO icon
19
DELISTED
Akero Therapeutics
AKRO
$5.82M 1.73%
249,254
+217,918
+695% +$4.3M
2022 Q2
6 quarters
PLRX icon
20
Pliant Therapeutics
PLRX
$59.9M
$5.77M 1.72%
318,524
+68,115
+27% +$1.04M
2022 Q3
5 quarters
ITCI icon
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.73M 1.71%
80,000
-128,730
-62% -$7.41M
2020 Q4
12 quarters
COGT icon
22
Cogent Biosciences
COGT
$4.87B
$5.68M 1.69%
966,748
+315,376
+48% +$2.42M
2020 Q4
12 quarters
ALPN icon
23
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.68M 1.69%
+297,789
New +$4.14M
2023 Q4
0 quarters
GOSS icon
24
Gossamer Bio
GOSS
$59.7M
$5.59M 1.67%
76,628
– –
2023 Q3
1 quarter
ISRG icon
25
Intuitive Surgical
ISRG
$149B
$5.33M 1.59%
+15,808
New +$4.71M
2023 Q4
0 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Silverarc Capital Management held 96 positions worth $336M, up 1.9% from $330M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Silverarc Capital Management's Q4 2023 filing shows 16 new, 28 increased, 16 reduced and 29 closed positions. Its largest new stake was Nuvalent: 193,000 shares worth $14.2M. The largest sale was Immunogen Inc, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Silverarc Capital Management's largest Q4 2023 buy was Nuvalent: 193,000 shares worth $14.2M.
  • Silverarc Capital Management added most to Akero Therapeutics in Q4 2023, an estimated $4.3M increase.
  • Silverarc Capital Management's biggest Q4 2023 reduction was Soleno Therapeutics, cutting an estimated $8.43M.
  • Silverarc Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $20.7M.
  • Silverarc Capital Management's ten largest holdings make up 39% of its $336M portfolio in Q4 2023.
  • Silverarc Capital Management opened 16 new positions and closed 29 in Q4 2023.
  • Silverarc Capital Management's portfolio value rose 1.9% quarter-over-quarter to $336M.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.